Alternative pre-mRNA splicing in digestive tract malignancy

Cancer Science

Volumn 102, Issue 2, 2011, Pages 309-316

  Miura, Koh ^a   Fujibuchi, Wataru ^b   Sasaki, Iwao ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BENZOTHIAZOLE; CD44V ANTIGEN; CD82 ANTIGEN; MESSENGER RNA PRECURSOR; MISMATCH REPAIR PROTEIN; NATURAL PRODUCT; PLADIENOLIDE; PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; SPLICEOSTATIN A; SURVIVIN; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ALTERNATIVE RNA SPLICING; CANCER LOCALIZATION; CANCER PATIENT; CHROMOSOME ABERRATION; CIS TRANS ISOMERISM; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM; DIGESTIVE SYSTEM CANCER; DRUG DESIGN; DRUG INHIBITION; EXON; FAMILIAL CANCER; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRON; MISMATCH REPAIR; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEOMICS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TRANS SPLICING;

ALTERNATIVE SPLICING; DIGESTIVE SYSTEM NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA PRECURSORS;

EID: 79952081852     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01797.x     Document Type: Review

References (50)

1. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell 2006; 126: 37-47.
2. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-945.
3. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001; 29: 2850-2859.
4. Lee C, Atanelov L, Modrek B, Xing Y. ASAP: the Alternative Splicing Annotation Project. Nucleic Acids Res 2003; 31: 101-105.
5. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72: 291-336.
6. Ohnuma S, Miura K, Horii A et al. Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues. Surgery 2009; 145: 57-68.
7. Burge CB, Tuschl T, Sharp PA. Splicing of precursors to mRNAs by the spliceosomes. In: Gesteland RF, Cech TR, Atkins JF, eds. The RNA World II. New York, NY: Cold Spring Harbor Laboratory Press, 1999; 525-560.
8. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009; 136: 701-718.
9. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10: 741-754.
10. Krecic AM, Swanson MS. hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol 1999; 11: 363-371.
11. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349-357.
12. Zahler AM, Neugebauer KM, Lane WS, Roth MB. Distinct functions of SR proteins in alternative pre-mRNA splicing. Science 1993; 260: 219-222.
13. Cáceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002; 18: 186-193.
14. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33: 591-601.
15. Singh R, Valcárcel J. Building specificity with nonspecific RNA-binding proteins. Nat Struct Mol Biol 2005; 12: 645-653.
16. McGlincy NJ, Smith CW. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem Sci 2008; 33: 385-393.
17. van Alphen RJ, Wiemer EA, Burger H, Eskens FA. The spliceosome as target for anticancer treatment. Br J Cancer 2009; 100: 228-232.
18. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109: 121-124.
19. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405.
20. Oliveira C, de Bruin J, Nabais S et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene 2004; 23: 2236-2240.
21. Lee SH, Kim WH, Kim HK et al. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 2001; 284: 850-855.
22. Tao H, Shinmura K, Hanaoka T et al. A novel splice-site variant of the base excision repair gene MYH is associated with production of an aberrant mRNA transcript encoding a truncated MYH protein not localized in the nucleus. Carcinogenesis 2004; 25: 1859-1866.
23. Shinmura K, Tao H, Yamada H et al. Splice-site genetic polymorphism of the human kallikrein 12 (KLK12) gene correlates with no substantial expression of KLK12 protein having serine protease activity. Hum Mutat 2004; 24: 273-274.
24. Stella A, Wagner A, Shito K et al. A nonsense mutation in MLH1 causes exon skipping in three unrelated HNPCC families. Cancer Res 2001; 61: 7020-7024.
25. McVety S, Li L, Gordon PH, Chong G, Foulkes WD. Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet 2006; 43: 153-156.
26. Pagenstecher C, Wehner M, Friedl W et al. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet 2006; 119: 9-22.
27. Lastella P, Surdo NC, Resta N, Guanti G, Stella A. In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 2006; 7: 243.
28. Aretz S, Uhlhaas S, Sun Y et al. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. Hum Mutat 2004; 24: 370-380.
29. De Rosa M, Morelli G, Cesaro E et al. Alternative splicing and nonsense-mediated mRNA decay in the regulation of a new adenomatous polyposis coli transcript. Gene 2007; 395: 8-14.
30. van Kuilenburg AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
31. Ghigna C, Moroni M, Porta C, Riva S, Biamonti G. Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res 1998; 58: 5818-5824.
32. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39: 527-579.
33. Klimek-Tomczak K, Mikula M, Dzwonek A et al. Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa. Br J Cancer 2006; 94: 586-592.
34. Matos P, Oliveira C, Velho S et al. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 2008; 135: 899-906.
35. Gonçalves V, Matos P, Jordan P. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Genet 2009; 18: 3696-3707.
36. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
37. Miura K, Karasawa H, Sasaki I. cIAP2 as a therapeutic target in colorectal cancer and other malignancies. Expert Opin Ther Targets 2009; 13: 1333-1345.
38. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-6102.
39. Krieg A, Mahotka C, Krieg T et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002; 86: 737-743.
40. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 2007; 4: 174-191.
41. Esufali S, Charames GS, Pethe VV, Buongiorno P, Bapat B. Activation of tumor-specific splice variant Rac1b by dishevelled promotes canonical Wnt signaling and decreased adhesion of colorectal cancer cells. Cancer Res 2007; 67: 2469-2479.
42. Matos P, Jordan P. Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells. J Biol Chem 2006; 281: 13724-13732.
43. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 2009; 37: 1207-1213.
44. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8: 880-887.
45. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999; 13: 3191-3197.
46. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
47. Kotake Y, Sagane K, Owa T et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007; 3: 570-575.
48. Kaida D, Motoyoshi H, Tashiro E et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007; 3: 576-583.
49. Muraki M, Ohkawara B, Hosoya T et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004; 279: 24246-24254.
50. Barash Y, Calarco JA, Gao W et al. Deciphering the splicing code. Nature 2010; 465: 53-59.